COMMENTARY: Adjuvant vs Neoadjuvant for Resectable NSCLC?

Which is better? Concurrent neoadjuvant chemotherapy and immunotherapy or concurrent adjuvant chemotherapy with immunotherapy for non–small cell lung cancer (NSCLC)?

Related Keywords

United States ,American , ,American Society Of Clinical Oncology ,European Society For Medical Oncology ,American Society ,Clinical Oncology ,Lancet Oncology ,New England Journal ,European Society ,Medical Oncology ,Patient Presents With Resectable ,Lung Cancer ,Ung Carcinoma ,Ancer Lung ,Chemotherapy ,Non Small Cell Lung Cancer ,Nsclc ,Neoplasm ,Tumor ,Adjuvant Chemotherapy ,Neoadjuvant ,Biologic Therapy ,Immunotherapy ,Surgery ,Clinical Research ,Clinical Trials ,Linical Studies ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Presection ,Biomarker ,Iological Marker ,Epidermal Growth Fa ,